Skip to content

Health economic effect of leuprorelin acetate depot injection for 6 months (brand) for premenopausal breast cancer patients compared to that for 3 months (generic).

Health economic effect of leuprorelin acetate depot injection for 6 months (brand) for premenopausal breast cancer patients compared to that for 3 months (generic). - Health economic effect of leuprorelin acetate depot injection for premenopausal breast cancer patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000024760
Enrollment
100
Registered
2016-11-08
Start date
2016-11-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: breast cancer patients

Exclusion criteria

Exclusion criteria: patients who cannot answer a questionnaire survey

Design outcomes

Primary

MeasureTime frame
Monetary value of reduced injection frequency

Countries

Japan

Contacts

Public ContactTomomi Takeshima

Millian Japan Healthcare Practice and Data Analysis

tomomi.takeshima@milliman.inc03-5211-7031

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026